JP2022525478A5 - - Google Patents

Info

Publication number
JP2022525478A5
JP2022525478A5 JP2021556493A JP2021556493A JP2022525478A5 JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5 JP 2021556493 A JP2021556493 A JP 2021556493A JP 2021556493 A JP2021556493 A JP 2021556493A JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5
Authority
JP
Japan
Application number
JP2021556493A
Other languages
Japanese (ja)
Other versions
JP2022525478A (ja
JPWO2020191344A5 (https=
JP7682797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023986 external-priority patent/WO2020191344A1/en
Publication of JP2022525478A publication Critical patent/JP2022525478A/ja
Publication of JP2022525478A5 publication Critical patent/JP2022525478A5/ja
Publication of JPWO2020191344A5 publication Critical patent/JPWO2020191344A5/ja
Priority to JP2025080864A priority Critical patent/JP2025122027A/ja
Application granted granted Critical
Publication of JP7682797B2 publication Critical patent/JP7682797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556493A 2019-03-20 2020-03-20 クローディン6二重特異性抗体 Active JP7682797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080864A JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821399P 2019-03-20 2019-03-20
US62/821,399 2019-03-20
PCT/US2020/023986 WO2020191344A1 (en) 2019-03-20 2020-03-20 Claudin-6 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080864A Division JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2022525478A JP2022525478A (ja) 2022-05-16
JP2022525478A5 true JP2022525478A5 (https=) 2023-03-29
JPWO2020191344A5 JPWO2020191344A5 (https=) 2023-03-29
JP7682797B2 JP7682797B2 (ja) 2025-05-26

Family

ID=72521273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556493A Active JP7682797B2 (ja) 2019-03-20 2020-03-20 クローディン6二重特異性抗体
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体

Country Status (6)

Country Link
US (1) US20220177583A1 (https=)
EP (1) EP3941944A4 (https=)
JP (2) JP7682797B2 (https=)
CN (1) CN114206934A (https=)
CA (1) CA3134056A1 (https=)
WO (1) WO2020191344A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
CA3212530A1 (en) * 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
JP2024511319A (ja) * 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Cd3及びcldn6に結合するヘテロ二量体抗体
KR20240004680A (ko) * 2021-05-07 2024-01-11 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
AU2022311053A1 (en) * 2021-07-15 2023-12-14 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
MX2023015028A (es) * 2021-09-01 2024-02-16 Biosceptre Aust Pty Ltd Nuevos aglutinantes del p2x7 disfuncional.
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
JPWO2023053282A1 (https=) * 2021-09-29 2023-04-06
EP4704916A1 (en) * 2023-04-29 2026-03-11 Innovent Biologics (Suzhou) Co., Ltd. Modified antibodies, antibody fragments thereof, and antibody-drug conjugates
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2022525478A5 (https=)
BR102021015566A2 (https=)
BR102021007978A2 (https=)
BR102020019899A2 (https=)
CN305527275S (https=)
CN305901389S (https=)
CN305535112S (https=)
CN305534854S (https=)
CN305915180S (https=)
CN305533502S (https=)
CN305532661S (https=)
CN305532340S (https=)
CN305532572S (https=)
CN305530118S (https=)
CN305530041S (https=)
CN305529949S (https=)
CN305529548S (https=)
CN305529100S (https=)
CN305529013S (https=)
CN305893527S (https=)
CN305527767S (https=)
CN305527746S (https=)
CN305539862S (https=)
CN305696499S (https=)
CN305917496S (https=)